FY2017 EPS Estimates for Conatus Pharmaceuticals Inc. Lifted by Analyst (CNAT)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Stock analysts at SunTrust Banks lifted their FY2017 earnings per share (EPS) estimates for shares of Conatus Pharmaceuticals in a research report issued to clients and investors on Thursday. SunTrust Banks analyst J. Boris now expects that the biotechnology company will post earnings of ($0.47) per share for the year, up from their previous forecast of ($0.53). SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.01) EPS and FY2018 earnings at $2.22 EPS.
A number of other research firms have also weighed in on CNAT. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Seaport Global Securities reissued a “buy” rating and issued a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $16.00.
WARNING: “FY2017 EPS Estimates for Conatus Pharmaceuticals Inc. Lifted by Analyst (CNAT)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-conatus-pharmaceuticals-inc-lifted-by-analyst-cnat/1684998.html.
Conatus Pharmaceuticals (NASDAQ CNAT) opened at $4.26 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.77 and a quick ratio of 2.77.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 88.06%. The company had revenue of $9.57 million during the quarter, compared to analyst estimates of $16.06 million. During the same quarter last year, the business earned ($0.31) EPS.
Institutional investors and hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC purchased a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $101,000. Bank of Montreal Can purchased a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $109,000. FNY Partners Fund LP raised its stake in shares of Conatus Pharmaceuticals by 98.0% during the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 9,800 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth about $115,000. Finally, New York State Common Retirement Fund raised its stake in shares of Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 14,700 shares in the last quarter. 33.04% of the stock is owned by institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.